fda and semaglutide FDA Approves Oral Semaglutide: First GLP-1 Weight Loss Pill

On February 21, 2025, the FDA announced that semaglutide, the active ingredient in Ozempic and Wegovy, is no longer considered in shortage, signaling an improvement in national supply. As a result, compounding

20.46

★★★★☆4.8 (126)

FDA approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease

26.02

★★★★★4.9 (98)

FDA Clears Semaglutide For Cardiac Risk Reduction in Diabetic Patients

28.89

★★★★★5.0 (157)

New Weight Loss Medication Wegovy™ Approved by the FDA

26.71

★★★★★4.7 (84)

FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain

25.38

★★★★★4.9 (203)

FDA has approved a new oral form of semaglutide for long-term weight reduction in adults with obesity or overweight. The new oral tablet is also indicated for reducing the risk of major

26.96

★★★★★5.0 (176)

A big win for Wegovy: Weight loss drug semaglutide first in history to gain FDA approval for reducing heart risks

26.98

★★★★★4.8 (132)